Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Century Therapeutics (IPSC) over the last 4 years, with Q1 2025 value amounting to $120000.0.

  • Century Therapeutics' Cash from Financing Activities fell 9934.05% to $120000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was -$482000.0, marking a year-over-year decrease of 10064.43%. This contributed to the annual value of $74.6 million for FY2024, which is 86671.47% up from last year.
  • As of Q1 2025, Century Therapeutics' Cash from Financing Activities stood at $120000.0, which was down 9934.05% from -$602000.0 recorded in Q4 2024.
  • Century Therapeutics' 5-year Cash from Financing Activities high stood at $56.7 million for Q2 2024, and its period low was -$10.1 million during Q2 2023.
  • For the 4-year period, Century Therapeutics' Cash from Financing Activities averaged around $7.1 million, with its median value being $137000.0 (2022).
  • Per our database at Business Quant, Century Therapeutics' Cash from Financing Activities plummeted by 2117708.33% in 2023 and then soared by 396138.39% in 2024.
  • Quarter analysis of 4 years shows Century Therapeutics' Cash from Financing Activities stood at $95000.0 in 2022, then crashed by 474.74% to -$356000.0 in 2023, then crashed by 69.1% to -$602000.0 in 2024, then skyrocketed by 119.93% to $120000.0 in 2025.
  • Its last three reported values are $120000.0 in Q1 2025, -$602000.0 for Q4 2024, and $273000.0 during Q3 2024.